Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
Pfizer Inc. reports developments across its global biopharmaceutical business, including prescription medicines, vaccines, biosimilars, sterile injectables, and oncology therapies. Recurring news covers financial results and guidance, commercial portfolio changes within Biopharma, dividend declarations, capital allocation priorities, and product access initiatives for established medicines such as Eliquis.
Company updates also address clinical and regulatory activity across Pfizer's pipeline and marketed products. Recent themes include oncology data presentations, Phase 3 results for ELREXFIO in relapsed or refractory multiple myeloma, PADCEV combination regulatory activity in bladder cancer, VYNDAMAX patent litigation settlements, and shareholder meeting communications.
Pfizer (NYSE:PFE) reported positive Phase 2 data for its investigational 25-valent pneumococcal conjugate vaccine 25vPnC (PF-07872412) in infants versus PREVNAR 20.
25vPnC showed 8.8-fold and ~15-fold higher serotype 3 immunogenicity after Doses 3 and 4, a safety profile consistent with existing vaccines, and potential coverage of ~90% of disease-causing serotypes, supporting initiation of a pivotal pediatric Phase 3 program and advancement of a 35-valent adult candidate.
Astellas (NYSE:PFE) will present 10 oncology-related abstracts at the ASCO 2026 meeting, including two oral presentations, covering urothelial carcinoma, prostate cancer, women’s health and pipeline programs.
Data span long-term outcomes, quality of life, subgroup analyses, and a trial-in-progress of fezolinetant and TROP2-targeted ADC ASP2998.
Pfizer (NYSE:PFE) received European Commission approval to expand HYMPAVZI (marstacimab) for adults and adolescents ≥12 years with hemophilia A or B with inhibitors, weighing ≥35 kg.
Phase 3 data showed a 93% reduction in mean treated annualized bleeding rate versus on-demand therapy, with sustained benefit and a once-weekly subcutaneous regimen.
Pfizer (NYSE: PFE) reported Q1 2026 revenue of $14.5 billion (2% operational growth) and reaffirmed full-year 2026 guidance: revenues $59.5–$62.5 billion and adjusted diluted EPS $2.80–$3.00. Reported diluted EPS was $0.47; adjusted diluted EPS was $0.75. Launched and acquired products grew 22% operationally. Pipeline momentum includes positive Phase 3 and mid-stage readouts and the company is on track to start ~20 key pivotal studies in 2026. Q1 capital deployment: $2.5B R&D, ~$110M business development, $2.4B dividends; no repurchases in 2026 planned.
Pfizer (NYSE: PFE) announced that the Phase 3 MagnetisMM-5 trial of ELREXFIO (elranatamab) met its primary endpoint at an interim analysis on April 29, 2026, showing a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus daratumumab+pomalidomide+dexamethasone (DPd).
Safety was consistent with ELREXFIO’s known profile with no new safety signals. Overall survival remains immature and the trial is ongoing; detailed data will be submitted for a future medical congress and discussed with global health authorities.
Pfizer (NYSE: PFE) said it reached settlement agreements with Dexcel Pharma, Hikma Pharmaceuticals and Cipla, extending the effective U.S. patent expiry for VYNDAMAX (tafamidis) to June 1, 2031, subject to other litigation outcomes. Revenues are expected to remain relatively stable from 2028 through mid-2031. VYNDAMAX holds 75% prescription volume in the ATTR-CM market. Pfizer discontinued U.S. supply of VYNDAQEL as of Dec 31, 2025, leaving VYNDAMAX available for eligible patients.
Bristol Myers Squibb (BMY) and Pfizer announced that Eliquis (apixaban) will be sold on Mark Cuban Cost Plus Drug Company starting April 27, 2026, offering a 30-day supply for a total cash price of $345. The move expands direct-to-patient access for cash-paying customers alongside the existing Eliquis 360 Support option.
The announcement reiterates Eliquis indications for AFib, DVT/PE, and post-orthopedic surgery, and includes Important Safety Information about bleeding risks and use limitations.
Pfizer (NYSE: PFE) declared a $0.43 per-share quarterly cash dividend for second-quarter 2026, payable June 12, 2026 to holders of record at the close of business on May 8, 2026.
This will be Pfizer's 350th consecutive quarterly dividend.
Pfizer (NYSE: PFE) will present new oncology data at ASCO 2026 (May 29–June 2) covering over 40 abstracts, including three late-breaking sessions and eight oral presentations.
Key highlights include a 7‑year CROWN update supporting lorlatinib as first-line ALK+ NSCLC, BREAKWATER PFS/OS data for a BRAFTOVI regimen in BRAF V600E mCRC, TALAPRO-3 topline rPFS benefit for TALZENNA + XTANDI in mCSPC, and HER2CLIMB-05 maintenance results for TUKYSA. Multiple next-generation programs (PF‑08634404, sigvotatug vedotin, atirmociclib) advance toward Phase 3 testing.
Astellas and Pfizer (NYSE: PFE) announced the FDA has accepted for Priority Review a supplemental BLA for perioperative PADCEV (enfortumab vedotin) plus Keytruda (pembrolizumab) to treat muscle-invasive bladder cancer (MIBC) regardless of cisplatin eligibility. EV-304 Phase 3 data showed a 47% reduction in risk of recurrence/progression and a 35% reduction in risk of death; pCR was 55.8% vs 32.5% for chemotherapy. The PDUFA target action date is August 17, 2026.